All microarray CEL files are available from the NCBI GEO database (accession number GSE63154).

Introduction {#sec001}
============

Myostatin (MSTN), also known as GDF8, is a transforming growth factor beta (TGFβ) superfamily member that negatively regulates skeletal muscle growth in various species \[[@pone.0117607.ref001]--[@pone.0117607.ref003]\]. Previous studies have demonstrated that MSTN blockade can functionally improve dystrophic muscle \[[@pone.0117607.ref004]\] and that MSTN can also play an important role in adipose development \[[@pone.0117607.ref005]\]. To better understand the molecular mechanisms by which MSTN controls muscle growth and development, microarray data from MSTN-null and wild-type mice were used for gene co-expression network analysis during key timepoints in skeletal muscle development. These timepoints included primary myogenesis at 13.5 days post coitus (d.p.c.), secondary myogenesis at 17.5 d.p.c., and postnatal muscle growth at 35 days after birth (d35) \[[@pone.0117607.ref006]--[@pone.0117607.ref008]\].

In previous studies, the partial correlation and information theory (PCIT) approach and the regulatory impact factor (RIF) algorithm have been used to evaluate the regulatory functions of transcription factors (TFs) on gene expression \[[@pone.0117607.ref009]--[@pone.0117607.ref011]\]. The PCIT algorithm can be used to determine the differential hubbing (DH; \[[@pone.0117607.ref009]\]) of targets to putative regulatory genes. A regulator that exhibits DH across treatments will have drastically higher connectivity in one treatment compared to the others. The RIF algorithm identifies potential regulators that are "differentially wired" (i.e., differentially correlated) as a function of treatment (*Mstn* genotype, in the context of this study). Two methods for calculating RIF assign different weights to the target gene's level of expression. The RIF1 score also ranks genes based on their phenotypic impact factor (PIF; a score that combines overall expression and differential expression). RIF1 scores place more emphasis on target transcripts highly differentially wired due to treatment, while RIF2 scores identify regulators whose expression tends to predict changes in expression of target transcripts that are differentially expressed (DE) between treatments. Previous studies evaluating RIF scores demonstrate that genes with relatively stable expression levels in different conditions (i.e., genes not differentially expressed) can still play important roles in biological processes in a coordinated manner. But these studies have limitations: first, these analyses mainly considered DE genes, which were quite limited and may not be representative of all the changes that take place in response to an experimental treatment. Second, only genes with known regulatory functions (i.e., transcription factors) were evaluated in previous studies. Without considering all genes, it is difficult to discover novel regulators of skeletal muscle growth.

In this study, we applied modified versions of the PCIT \[[@pone.0117607.ref012]\] and RIF algorithms \[[@pone.0117607.ref010],[@pone.0117607.ref011]\] to evaluate more than 34,000 annotated genes from a whole microarray dataset as potential regulators of muscle and adipose development in the presence or absence of functional myostatin. We consider the RIF method modified because all genes were tested as possible regulators using RIF scores, whereas previous studies using this methodology considered only TFs as possible regulators. The PCIT method utilized in this anlaysis used the same methodology but was computationally enhanced to complete the analysis in considerably less time than the original algorithm \[[@pone.0117607.ref012]\]. We calculated RIF scores that contrasted *Mstn* genotypes at each developmental timepoint to identify potential regulators of *Mstn* or pathways influenced by MSTN signal transduction. Furthermore, DE genes were compared across *Mstn* genotypes for differences in the enrichment of TF binding sites, biological processes, and pathways related to MSTN function.

Materials and Methods {#sec002}
=====================

Ethics Statement {#sec003}
----------------

This study was carried out in strict accordance with the recommendations in the Animal Guide of the United States Department of Agriculture. The protocol was approved by the Institutional Animal Care and Use committee of Iowa State University (Protocol Number: 11-05-6013-M).

Animals and sample collection {#sec004}
-----------------------------

Animals were reared, sacrificed by CO~2~ asphyxiation (embryonic timepoints) or cervical dislocation (d35), and tissues were collected from whole embryos (13.5 d.p.c.), hindquarters (17.5 d.p.c.), or pectoralis muscle (d35). The pectoralis muscle was chosen at day 35 because it is the muscle with the greatest change in muscle mass due to *Mstn* deletion and had a high level of myostatin expression as described in the original paper characterizing myostatin function in skeletal muscle \[[@pone.0117607.ref002]\]. After collection, muscles were flash-frozen in liquid nitrogen as previously described \[[@pone.0117607.ref013]\].

RNA isolation and target preparation {#sec005}
------------------------------------

The frozen tissues from whole embryo or hindquarter only were immersed in RLT lysis buffer (Qiagen, Valencia, CA) and homogenized for 45 seconds, then centrifuged at 3600g for 10 min to pellet cell debris. Total RNA was isolated using the RNase Midi Kit (Qiagen) with on-column DNase digestion according to manufacturer\'s protocol. Isolation from pectoralis muscle was conducted as described \[[@pone.0117607.ref013]\]. The concentration of isolated RNA was evaluated based on absorbance at 260 nm and the quality was determined by agarose gel electrophoresis. For microarray analysis, 10 μg of RNA from each of three individual animals was pooled to give five pools representing 15 indviduals for each genotype/timepoint combination. A final concentration of 1 μg/ml was yielded from the pooled RNA, the quality of which was reconfirmed using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Microarray target preparation, hybridization, and scanning were conducted as described \[[@pone.0117607.ref013]\].

Microarray processing {#sec006}
---------------------

Target RNA was hybridized to both chip A and chip B of the GeneChip Mouse Expression Set 430 (MOE430; Affymetrix, Santa Clara, CA), which includes over 45,000 probe sets and 39,000 transcripts and variants, containing over 34,000 well-annotated mouse genes. Robust multi-array analysis (RMA) was performed to normalize the raw data \[[@pone.0117607.ref014]\] by using R/affy package \[[@pone.0117607.ref015]\]. All of the microarray data is available at NCBI GEO under accession number GSE63154.

Statistical analysis {#sec007}
--------------------

The normalized gene expression data were used for further analysis. To detect differentially expressed genes in each genotype, expression data with five replicates were analyzed as a completely randomized design by using R/limma package \[[@pone.0117607.ref016]\]. Because the tissues are different across timepoints, the analysis was performed separately for each timepoint. The model used for analysis was, where y~ij~ is the normalized gene expression, μ is the overall mean, G~i~ is the ith genotype, and ε~ij~ is the error for the jth replicate within the ith genotype. DE genes were identified at a false discovery rate (FDR) \<0.05 using the q-value package from Bioconductor \[[@pone.0117607.ref017]\].

RIF analysis and differential hubbing {#sec008}
-------------------------------------

Using all of the Affy ProbesetIDs after excluding the control IDs and housekeeping genes, we applied a modified partial correlation and information theory approach (PCIT) \[[@pone.0117607.ref010],[@pone.0117607.ref012]\] to compute the co-expression correlation between each gene pair in both MSTN-null and wild-type conditions. Co-expression analyses were done only within timepoint since tissue types were not identical across different developmental stages. As described in Reverter et al. \[[@pone.0117607.ref011]\], we calculated the regulatory impact factors (RIF), which compute the differential wiring from the difference in co-expression correlation of each pair of genes. A key difference in this analysis is that we used all genes for the RIF analysis to try to identify novel regulators of muscle growth in response to lack of functional MSTN. Differential hubbing calculations were conducted using a Perl script that captured only the significant partial correlations identified by the PCIT algorithm. Correlates were filtered to include only those genes with \|r\| ≥ 0.90 to ensure that only strong correlations were captured, given the small sample size and large amount of data. The concept of RIF, PIF, and differential hubbing can be challenging to understand in the context of biological processes. Hudson et al. \[[@pone.0117607.ref009]\] provide a nice description of how these co-expression methods can be used to understand the genetic regulation of muscle mass.

Annotation and pathway analysis {#sec009}
-------------------------------

Annotation of ProbesetIDs is based on the annotation file from the Affymetrix website (<http://www.affymetrix.com>), while the IDs without annotation were annotated using Biomart (Ensembl, <http://www.ensembl.org/biomart/martview/c56c1fc10cb311e0b5fe1c05dbd3f217>) and DAVID \[[@pone.0117607.ref018]\]. Differentially expressed genes and genes co-correlated to top RIF were used to identify over-represented pathways across different developmental timepoints in web-based DAVID, while the significant regulators of these gene lists were analyzed in Sub-Network Enrichment Analysis (SNEA) via Pathway Studio \[[@pone.0117607.ref019]\].

Discovering significantly over-represented motifs using DREME {#sec010}
-------------------------------------------------------------

Among those genes up- and downregulated between genotypes as well as co-expressed with top RIF regulators, we applied a motif discovery method for non-redundant, statistically significant, and discriminative motifs using Discriminative Regular Expression Motif Elicitation (DREME) \[[@pone.0117607.ref020]\] implemented in iPlant (<http://www.iplantcollaborative.org>). We used 1,500 bp upstream flanking sequence in FASTA format. Generally, we ran the analysis using the default settings. First, the sequences of genes of interest from up- and downregulated groups were used for positive input sequences, while the negative sequences were the sequences of well-annotated genes from both MOE430A and MOE430B chips after excluding those genes of interest. Second, we chose 3 as the minimum width of core motif and 8 as the maximum. Third, 0.05 was chosen as the motif e-value cutoff, where the e-value is the motif statistic p-value times the number of candidate motifs tested, and the counts created after removing sites that matched motifs found previously were used to calculate the p-value.

To evaluate the discovered motifs, we used TOMTOM \[[@pone.0117607.ref021]\] implemented in MEME Suite (<http://meme.nbcr.net/meme/intro.html>) to compare the motifs with the database of known transcription factor motifs in JASPAR (JASPAR_CORE_2009.meme; 476 motifs) \[[@pone.0117607.ref022]\] and UniProbe (uniprobe_mouse.meme; 386 motifs) \[[@pone.0117607.ref023]\] using default settings with the significance threshold 0.05.

Results {#sec011}
=======

Differentially expressed genes {#sec012}
------------------------------

[Table 1](#pone.0117607.t001){ref-type="table"} and [Table 2](#pone.0117607.t002){ref-type="table"} present the top 20 DE genes ranked by significance at 13.5 d.p.c. and d35, respectively. The DE genes were identified using R/limma ([S1 Table](#pone.0117607.s002){ref-type="supplementary-material"}) and a significance threshold of FDR \< 0.05. At 13.5 d.p.c., 283 genes were DE, 17 of which were downregulated and 266 of which were upregulated in WT. Surprisingly, we did not identify any differentially expressed genes (FDR \< 0.05) at 17.5 d.p.c. At d35, 2034 genes were DE, 928 of which were downregulated and 1106 of which were upregulated in wild-type mice.

10.1371/journal.pone.0117607.t001

###### Top 20 WT/null differentially expressed genes ranked by significance at 13.5 d.p.c., q \< 0.05[\*](#t001fn001){ref-type="table-fn"}.

![](pone.0117607.t001){#pone.0117607.t001g}

  ProbesetID      Fold Change[^\^^](#t001fn002){ref-type="table-fn"}   q-Value    Change Direction   Gene Symbol   Gene Description
  --------------- ---------------------------------------------------- ---------- ------------------ ------------- ------------------------------------------------------------------------------------
  1419356_at      1.94                                                 1.44E-05   Up                 Klf7          Kruppel-like factor 7 (ubiquitous)
  1456257_at      0.62                                                 0.0118     Down               Fam126b       family with sequence similarity 126, member B
  1431686_a\_at   1.22                                                 0.0130     Up                 Gmfb          glia maturation factor, beta
  1418170_a\_at   1.26                                                 0.0130     Up                 Zcchc14       zinc finger, CCHC domain containing 14
  1427353_at      1.27                                                 0.0130     Up                 Clasp1        CLIP associating protein 1
  1422528_a\_at   1.28                                                 0.0130     Up                 Zfp36l1       zinc finger protein 36, C3H type-like 1
  1456398_at      1.29                                                 0.0130     Up                 TUG1          taurine upregulated gene 1
  1451730_at      1.29                                                 0.0130     Up                 Zfp62         zinc finger protein 62
  1431326_a\_at   1.29                                                 0.0130     Up                 Tmod2         tropomodulin 2
  1449118_at      1.34                                                 0.0130     Up                 Dbt           dihydrolipoamide branched chain transacylase E2
  1436746_at      1.41                                                 0.0130     Up                 Wnk1          WNK lysine deficient protein kinase 1
  1426756_at      1.41                                                 0.0130     Up                 Galnt2        UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2
  1419038_a\_at   1.58                                                 0.0130     Up                 Csnk2a1       casein kinase 2, alpha 1 polypeptide
  1431239_at      1.18                                                 0.0135     Up                 Nono          non-POU-domain-containing, octamer binding protein
  1424398_at      1.26                                                 0.0135     Up                 Dhx36         DEAH (Asp-Glu-Ala-His) box polypeptide 36
  1426777_a\_at   1.43                                                 0.0139     Up                 Wasl          Wiskott-Aldrich syndrome-like (human)
  1417623_at      1.18                                                 0.0142     Up                 Slc12a2       solute carrier family 12, member 2
  1455886_at      1.26                                                 0.0142     Up                 Cbl           Casitas B-lineage lymphoma
  1445199_at      1.22                                                 0.0149     Up                 PATZ1         POZ (BTB) and AT hook containing zinc finger 1
  1457513_at      1.22                                                 0.0149     Up                 Fam40a        family with sequence similarity 40, member A

\*For multiple probesetIDs with the same annotation, the probesetID with smallest q-value was saved.

^\^^Fold changes are presented as WT/null. Fold change \> 1 indicates higher expression in the WT compared to the null. Fold change \< 1 indicates higher expression in the null genotype compared to the WT.

10.1371/journal.pone.0117607.t002

###### Top 20 WT/null differentially expressed genes ranked by significance at d35, q \< 0.05[\*](#t002fn001){ref-type="table-fn"}.

![](pone.0117607.t002){#pone.0117607.t002g}

  ProbesetID      Fold Change[^\^^](#t002fn002){ref-type="table-fn"}   q-Value    Change Direction   Gene Symbol   Gene Description
  --------------- ---------------------------------------------------- ---------- ------------------ ------------- ----------------------------------------------------------
  1451203_at      2.28                                                 5.65E-06   Up                 Mb            Myoglobin
  1416551_at      3.74                                                 5.65E-06   Up                 Atp2a2        ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
  1427768_s\_at   3.80                                                 1.07E-05   Up                 Myl3          myosin, light polypeptide 3
  1449997_at      4.74                                                 1.47E-05   Up                 Tpm3          tropomyosin 3, gamma
  1448152_at      0.40                                                 1.67E-05   Down               Igf2          insulin-like growth factor 2
  1419606_a\_at   5.50                                                 1.67E-05   Up                 Tnnt1         troponin T1, skeletal, slow
  1455450_at      1.76                                                 1.92E-05   Up                 Ptpn3         protein tyrosine phosphatase, non-receptor type 3
  1424831_at      0.63                                                 2.28E-05   Down               Cpne2         copine II
  1448554_s\_at   4.36                                                 2.28E-05   Up                 Myh6          myosin, heavy polypeptide 6, cardiac muscle, alpha
                                                                                                     Myh7          myosin, heavy polypeptide 7, cardiac muscle, beta
  1450813_a\_at   4.30                                                 5.98E-05   Up                 Tnni1         troponin I, skeletal, slow 1
  1418370_at      4.93                                                 5.98E-05   Up                 Tnnc1         troponin C, cardiac/slow skeletal
  1417959_at      0.64                                                 6.51E-05   Down               Pdlim7        PDZ and LIM domain 7
  1417673_at      1.77                                                 6.51E-05   Up                 Grb14         growth factor receptor bound protein 14
  1437025_at      0.49                                                 7.72E-05   Down               Cd28          CD28 antigen
  1425153_at      1.82                                                 7.72E-05   Up                 Myh2          myosin, heavy polypeptide 2, skeletal muscle, adult
  1448394_at      5.08                                                 8.62E-05   Up                 Myl2          myosin, light polypeptide 2, regulatory, cardiac, slow
  1419145_at      2.06                                                 9.75E-05   Up                 Smtnl1        smoothelin-like 1
  1424937_at      1.58                                                 9.98E-05   Up                 Plin5         perilipin 5
  1422813_at      0.60                                                 1.01E-04   Down               Cacng1        calcium channel, voltage-dependent, gamma subunit 1
  1418865_at      0.60                                                 1.06E-04   Down               Zfp385a       zinc finger protein 385A

\*For multiple probesetIDs with the same annotation, the probesetID with smallest q-value was saved.

^\^^Fold changes are presented as WT/null. Fold change \> 1 indicates higher expression in the WT compared to the null. Fold change \< 1 indicates higher expression in the null genotype compared to the WT.

DAVID annotation and Pathway Studio analysis of DE genes at 13.5 d.p.c. and d35 {#sec013}
-------------------------------------------------------------------------------

Pathway analysis results from DAVID and Pathway Studio 9 are listed in [S2](#pone.0117607.s003){ref-type="supplementary-material"} and [S3](#pone.0117607.s004){ref-type="supplementary-material"} Tables. The 283 genes DE at 13.5 d.p.c. were significantly enriched for 46 Gene Ontology (GO) terms \[[@pone.0117607.ref024]\] and several PANTHER pathway terms and SP_PIR_KEYWORDS \[[@pone.0117607.ref018]\]. Most of the 13.5 d.p.c. DE genes were involved in the regulation of transcription, RNA processing, negative regulation of cellular biosynthetic process and transcription, nucleotide binding, transcription repressor activity, and WNT signaling pathway. For the 2034 genes DE at d35, 58 GO terms, 19 SP_PIR_KEYWORDS, and several KEGG and PANTHER pathway terms were over represented. The DE genes at d35 were largely involved in muscle organ/tissue development, fatty acid metabolism, and mitochondria. Pathway Studio results at d35 identified 100 significantly over-represented regulator-target relationships (p \< 0.05); PPARG, LEP, calmodulin, and GH1 were linked to the largest numbers of differentially expressed genes. MEF2A, MEF2C, creatine kinase, and UCP2 were also significantly enriched in the regulator-target relationships.

Over-represented DNA motifs in differentially expressed genes {#sec014}
-------------------------------------------------------------

[Fig. 1](#pone.0117607.g001){ref-type="fig"} and [Fig. 2](#pone.0117607.g002){ref-type="fig"} illustrate the over-represented motifs present in the promoters of DE genes at 13.5 d.p.c. (E-values \< 0.05). Ten and eleven over-represented motifs were identified in DE genes upregulated in WT and MSTN--null genotypes, respectively. Over-represented motifs at d35 are listed in Figures A and B in [S1 File](#pone.0117607.s001){ref-type="supplementary-material"}. At this timepoint, nine and ten over-represented motifs were identified in DE genes upregulated in WT and MSTN-null genotypes, respectively. Similar to the 13.5 d.p.c. timepoint, enriched motifs were identified in zinc-finger protein binding sites. Moreover, the SMAD3 binding site was identified as an over-represented motif in DE genes upregulated in the MSTN-null genotype, and the SP1 binding site was found to be the sixth most significant motif in DE genes upregulated in the WT.

![Over-represented motifs in genes upregulated in WT at 13.5 d.p.c.](pone.0117607.g001){#pone.0117607.g001}

![Over-represented motifs in genes upregulated in MSTN-null at 13.5 d.p.c.](pone.0117607.g002){#pone.0117607.g002}

Regulatory impact factor analysis {#sec015}
---------------------------------

Tables [3](#pone.0117607.t003){ref-type="table"}--[6](#pone.0117607.t006){ref-type="table"} list the top ten most extreme RIF scores, ranked by Z-score, at 13.5 d.p.c. and d35. All RIF scores are provided in [S4 Table](#pone.0117607.s005){ref-type="supplementary-material"}. [Fig. 3](#pone.0117607.g003){ref-type="fig"} shows the relationship between RIF1 and RIF2 scores for the 13.5 d.p.c. and d35 timepoints. The correlation coefficient (r) between RIF1 and RIF2 was very close to zero at 13.5 d.p.c. (r = -0.09) and moderately positive at d35 (r = 0.45). At 13.5 d.p.c., *Rps29* and *Beta-s* exhibited the top two RIF1 Z-scores (10.09 and 8.25, respectively). At d35 after birth, *Tnni2* and *Tpm1* exhibited the top two RIF1 Z-scores (11.24 and 10.01, respectively). At 13.5 d.p.c., *Cox6b1* and *Rpl13a* exhibited the top two RIF2 Z-scores (5.79 and 5.37, respectively), and at d35, *Atp2a2* and *Tnni2* exhibited the top two RIF2 Z-scores (7.84 and 7.74, respectively). Several genes were identified with top-ten RIF scores at both timepoints (i.e., *Beta-s*, *GM10420*, *March-2*). In addition, *Tnni2* was identified in the top ten at d35 for both RIF1 and RIF2. Target genes highly connected to *Tnni2* (Pearson correlation coefficient based on PCIT, \|r\| ≥ 0.9) were further investigated using ontology enrichment analysis to identify potential pathways involved in muscle development. Genes highly correlated with *Tnni2* in wild-type mice were enriched in the KEGG pathways viral myocarditis, immune/cancer, and proteolysis (adj.P, Benjamini \< 0.1; [S5 Table](#pone.0117607.s006){ref-type="supplementary-material"}). However, no KEGG terms were significantly enriched in *Tnni2* correlates in MSTN-null mice.

![Relationship between RIF1 and RIF2 at 13.5 d.p.c. and d35.](pone.0117607.g003){#pone.0117607.g003}

10.1371/journal.pone.0117607.t003

###### Top 10 RIF1 (wild type minus null) at 13.5 d.p.c.

![](pone.0117607.t003){#pone.0117607.t003g}

  ProbesetID                RIF1    RIF2    Gene Symbol              Gene Description
  ------------------------- ------- ------- ------------------------ -------------------------------------------
  \(1\) Top Positive RIF1                                            
  1415833_x\_at             10.09   -5.42   Rps29                    ribosomal protein S29
  1417184_s\_at             8.25    2.05    Beta-s, Hbb-b1, Hbb-b2   hemoglobin subunit beta-1-like
                                                                     hemoglobin, beta adult major chain
                                                                     hemoglobin, beta adult minor chain
  1416054_at                8.14    -2.80   Rps5                     ribosomal protein S5
  1416546_a\_at             7.81    -1.54   Rpl6                     ribosomal protein L6
  1417451_a\_at             7.74    -0.36   Ppia                     peptidylprolyl isomerase A
  \(2\) Top Negative RIF1                                            
  1415924_at                -2.50   0.23    Tnp1                     transition protein 1
  1416055_at                -2.50   0.24    Amy2a1, Amy2a2           amylase 2a1, amylase 2a2, amylase 2a3
                                            Amy2a3, Amy2a4, Amy2a5   amylase 2a4, amylase 2a5
  1418855_at                -2.49   -0.25   Lce1l                    late cornified envelope 1L
  1420239_x\_at             -2.45   0.21    March-2                  membrane-associated ring finger (C3HC4) 2
  1419792_at                -2.44   0.00    Kif20b                   kinesin family member 20B

10.1371/journal.pone.0117607.t004

###### Top 10 RIF2 (wild type minus null) at 13.5 d.p.c.

![](pone.0117607.t004){#pone.0117607.t004g}

  ProbesetID                RIF2     RIF1    Gene Symbol               Gene Description
  ------------------------- -------- ------- ------------------------- ----------------------------------------------------------------
  \(1\) Top Positive RIF2                                              
  1416565_at                5.79     7.00    Cox6b1                    cytochrome c oxidase, subunit VIb polypeptide 1
  1417608_a\_at             5.37     6.14    Rpl13a                    ribosomal protein L13A
  1423111_at                5.30     4.01    Atp5a1                    ATP synthase, H+ transporting, mitochondrial F1 complex
                                                                       alpha subunit 1
  1436992_x\_at             5.13     3.33    Vdac1                     voltage-dependent anion channel 1
  1417771_a\_at             5.00     3.25    Psmc6                     proteasome (prosome, macropain) 26S subunit, ATPase, 6
  \(2\) Top Negative RIF2                                              
  1435873_a\_at             -13.49   0.39    Gm11478, Rpl13a           60S ribosomal protein L13a-like, ribosomal protein L13A
                                             Zfp526                    zinc finger protein 526
  1416141_a\_at             -8.12    6.90    Rps6, Rps6-ps4            ribosomal protein S6, ribosomal protein S6, pseudogene 4
  1431765_a\_at             -7.49    7.41    Gm10420, Gm5978, Gm6139   predicted gene 10420, predicted gene 5978, predicted gene 6139
                                             Gm8225, Gm8842, Rps2      predicted gene 8225, predicted gene 8842, ribosomal protein S2
  1415906_at                -5.50    6.79    Tmsb4x                    thymosin, beta 4, X chromosome
  1415833_x\_at             -5.42    10.09   Rps29                     ribosomal protein S29

10.1371/journal.pone.0117607.t005

###### Top 10 RIF1 (wild type minus null) at d35.

![](pone.0117607.t005){#pone.0117607.t005g}

  ProbesetID                RIF1    RIF2    Gene Symbol       Gene Description
  ------------------------- ------- ------- ----------------- -------------------------------------------------------------
  \(1\) Top Positive RIF1                                     
  1416889_at                11.24   -0.92   Tnni2             troponin I, skeletal, fast 2
  1423049_a\_at             10.01   -0.50   Tpm1              tropomyosin 1, alpha
  1416478_a\_at             9.46    1.25    Mdh2              malate dehydrogenase 2, NAD (mitochondrial)
  1416921_x\_at             9.38    1.40    Aldoa, Aldoart1   aldolase A, fructose-bisphosphate, aldolase 1 A retrogene 1
  1417184_s\_at             9.32    2.05    Beta-s            hemoglobin subunit beta-1-like
                                            Hbb-b1            hemoglobin, beta adult major chain
                                            Hbb-b2            hemoglobin, beta adult minor chain
  \(2\) Top Negative RIF1                                     
  1417051_at                -2.11   -0.04   Pcdh8             protocadherin 8
  1420239_x\_at             -2.08   0.21    March2            membrane-associated ring finger (C3HC4) 2
  1416744_at                -2.07   0.20    Uap1              UDP-N-acetylglucosamine pyrophosphorylase 1
  1416967_at                -2.07   -1.26   Sox2              SRY-box containing gene 2
  1417256_at                -2.03   0.08    Mmp13             matrix metallopeptidase 13

10.1371/journal.pone.0117607.t006

###### Top 10 RIF2 (wild type minus null) at d35.

![](pone.0117607.t006){#pone.0117607.t006g}

  ProbesetID                RIF2    RIF1    Gene Symbol                                     Gene Description
  ------------------------- ------- ------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  \(1\) Top Positive RIF2                                                                   
  1416551_at                7.84    4.1     Atp2a2                                          ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
  1416889_at                7.74    11.24   Tnni2                                           troponin I, skeletal, fast 2
  1419606_a\_at             7.00    2.41    Tnnt1                                           troponin T1, skeletal, slow
  1416850_s\_at             6.72    5.34    Cisd1                                           CDGSH iron sulfur domain 1
  1417889_at                6.66    6.21    Apobec2                                         apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2
  \(2\) Top Negative RIF2                                                                   
  1423255_at                -4.1    2.6     Atp6v1g1                                        ATPase, H+ transporting, lysosomal V1 subunit G1
  1422156_a\_at             -3.76   5.27    Gm10420, Gm5978, Gm6139, Gm8841, Gm8842, Rps2   predicted gene 1042, predicted gene 597, predicted gene 6139, predicted gene 8841, predicted gene 8842, ribosomal protein S2
  1426731_at                -3.43   4.78    Des                                             desmin
  1422613_a\_at             -3.32   4.8     Gm11362, Rpl7a                                  predicted gene 11362, ribosomal protein L7A
  1418996_a\_at             -3.17   1.96    Lyrm5                                           LYR motif containing 5

Differential hubbing {#sec016}
--------------------

Differential hubbing scores are listed in [S6 Table](#pone.0117607.s007){ref-type="supplementary-material"}. [Fig. 4](#pone.0117607.g004){ref-type="fig"} illustrates extreme DH observed for *Ctnna1*, *Bmp8b*, and *Myl3* in wild-type vs. MSTN-null mice for highly correlated target genes (\|r\| ≥ 0.9). For instance, there were over 2,000 genes highly co-expressed (correlated) with *Ctnna1* in MSTN-null mice, but only one gene was highly co-expressed with *Ctnna1* in wild type at 13.5 d.p.c. Interestingly, *Ctnna1* was not differentially expressed (q = 0.56). *Bmp8b* was also found to be differentially hubbed between wild-type and MSTN-null mice at 13.5 d.p.c.; over 3,000 genes were highly co-expressed with *Bmp8b* in wild-type mice, while less than 1,000 genes were highly co-expressed with *Bmp8b* in MSTN-null mice. [Fig. 5](#pone.0117607.g005){ref-type="fig"} contrasts the differences in expression patterns of genes highly correlated to *Myl3* across genotypes at d35. Expression data used in [Fig. 5](#pone.0117607.g005){ref-type="fig"} are listed in [S7 Table](#pone.0117607.s008){ref-type="supplementary-material"}. The 5,500 genes highly correlated to and co-expressed with *Myl3* in wild-type mice were almost always downregulated, whereas the 1,189 co-expressed genes in MSTN-null mice were almost exclusively upregulated at d35. In MSTN-null mice, the *Myl3* differentially hubbed correlates were enriched for the KEGG pathway term mmu04360: "Axon guidance". In contrast, those genes highly correlated with *Myl3* in wild-type mice were significantly enriched for the KEGG terms actin cytoskeleton, T/B cell receptor signaling, viral myocarditis, Huntington\'s disease, cancer pathways, and ubiquitin-mediated proteolysis (Benjamini p \< 0.10; [Table 7](#pone.0117607.t007){ref-type="table"}).

![Differential wiring of co-correlated genes between WT and MSTN-null mice (\|r\| ≥ 0.9).](pone.0117607.g004){#pone.0117607.g004}

![Heat map of genes highly correlated to *Myl3* in WT and MSTN-null mice at d35.](pone.0117607.g005){#pone.0117607.g005}

10.1371/journal.pone.0117607.t007

###### KEGG pathway analysis of genes highly correlated with *Myl3* at d35 in wild-type vs. MSTN-null mice.

![](pone.0117607.t007){#pone.0117607.t007g}

  Term                                                 Count   \%     PValue     List Total   Pop Hits   Pop Total   Fold Enrichment   Benjamini
  ---------------------------------------------------- ------- ------ ---------- ------------ ---------- ----------- ----------------- -----------
  mmu04810:Regulation of actin cytoskeleton            81      1.82   1.58E-06   1316         217        5738        1.63              2.98E-04
  mmu04010:MAPK signaling pathway                      93      2.09   5.21E-06   1316         265        5738        1.53              4.92E-04
  mmu04662:B cell receptor signaling pathway           37      0.83   9.30E-06   1316         80         5738        2.02              5.86E-04
  mmu03010:Ribosome                                    39      0.88   2.34E-05   1316         89         5738        1.91              1.11E-03
  mmu04650:Natural killer cell mediated cytotoxicity   49      1.10   2.93E-05   1316         122        5738        1.75              1.11E-03
  mmu04666:Fc gamma R-mediated phagocytosis            41      0.92   5.05E-05   1316         98         5738        1.82              1.59E-03
  mmu05340:Primary immunodeficiency                    20      0.45   8.99E-05   1316         36         5738        2.42              2.42E-03
  mmu04670:Leukocyte transendothelial migration        46      1.03   1.56E-04   1316         119        5738        1.69              3.68E-03
  mmu04062:Chemokine signaling pathway                 64      1.44   1.78E-04   1316         182        5738        1.53              3.72E-03
  mmu04660:T cell receptor signaling pathway           45      1.01   2.66E-04   1316         118        5738        1.66              5.02E-03
  mmu04520:Adherens junction                           32      0.72   3.52E-04   1316         76         5738        1.84              6.03E-03
  mmu04144:Endocytosis                                 68      1.53   4.54E-04   1316         202        5738        1.47              7.13E-03
  mmu05200:Pathways in cancer                          100     2.25   5.95E-04   1316         323        5738        1.35              8.61E-03
  mmu04142:Lysosome                                    44      0.99   6.75E-04   1316         119        5738        1.61              9.08E-03
  mmu04120:Ubiquitin mediated proteolysis              48      1.08   1.19E-03   1316         136        5738        1.54              1.49E-02
  mmu05416:Viral myocarditis                           35      0.79   2.33E-03   1316         94         5738        1.62              2.72E-02
  mmu04640:Hematopoietic cell lineage                  32      0.72   2.49E-03   1316         84         5738        1.66              2.74E-02
  mmu04612:Antigen processing and presentation         34      0.76   2.56E-03   1316         91         5738        1.63              2.65E-02
  mmu04360:Axon guidance                               45      1.01   3.15E-03   1316         131        5738        1.50              3.09E-02
  mmu05016:Huntington\'s disease                       58      1.30   5.71E-03   1316         183        5738        1.38              5.27E-02
  mmu02010:ABC transporters                            19      0.43   7.51E-03   1316         45         5738        1.84              6.56E-02
  mmu04514:Cell adhesion molecules (CAMs)              49      1.10   1.05E-02   1316         154        5738        1.39              8.67E-02

Discussion {#sec017}
==========

Interpretation of genes differentially expressed during primary myogenesis and postnatal skeletal muscle growth {#sec018}
---------------------------------------------------------------------------------------------------------------

Microarray analysis of tissues from MSTN-null and wild-type mice identified DE genes at both 13.5 d.p.c. and d35, whereas no DE genes (q \< 0.05) were identified at 17.5 d.p.c. Ideally, comparisons would have been made using the same tissue sample from each of the timepoints. However, obtaining single muscles from 13.5 d.p.c. and 17.5 d.p.c. embryos was not feasible due to their small size at these stages of development. An important consequence is that no comparisons can be made across timepoints in this study since the tissue types are not comparable. It is also important to note that results from 13.5 and 17.5 d.p.c. may reflect gene expression changes in tissues other than muscle, even though myostatin is predominantly expressed in muscle. We would also like to note that this study is a meta-analysis of a previous study and that, although there is significant overlap, the number of DE genes identified at d35 in this study differs from the results of the previous study in our lab \[[@pone.0117607.ref013]\]. This is because different statistical methods were used in these two analyses. Despite the difference in the methodology used to analyze differential expression in the current study, all of the DE genes validated by real-time qPCR in our previous study were also significantly DE in this study (q\<0.05; [S1 Table](#pone.0117607.s002){ref-type="supplementary-material"}) \[[@pone.0117607.ref013]\].

Ontology-based enrichment analysis identified biological processes related to myostatin-mediated changes in skeletal muscle growth and metabolism. {#sec019}
--------------------------------------------------------------------------------------------------------------------------------------------------

DAVID ontology enrichment analyses identified significantly over-represented regulators relevant to both muscle and adipose development. At 13.5 d.p.c., over-representation of the WNT KEGG pathway was identified for genes DE by genotype. This result is consistent with a previous study from our lab that also identified a major role for WNT signal transduction in MSTN-mediated skeletal muscle growth at the d35 postnatal timepoint \[[@pone.0117607.ref013]\]. The DE genes at d35 were enriched for the DAVID terms muscle organ/tissue development, fatty acid metabolism, and mitochondria, which are all relevant to muscle and adipose growth. All DAVID results are presented in [S2 Table](#pone.0117607.s003){ref-type="supplementary-material"}.

MicroRNA-regulated gene networks were over represented at 13.5 d.p.c. {#sec020}
---------------------------------------------------------------------

Pathway Studio identified potential regulators within DE gene lists based on text mining of previously published results. Several microRNAs were identified as potential regulators from the sub-network analysis at 13.5 d.p.c., including *Mir29b1*, *Let7g*, *Mir139*, and *Mir122*. Since microRNAs are involved in many early developmental processes, it is possible that they may be involved in muscle and adipose development in pathways upstream or downstream of MSTN signaling.

Fatty acid metabolism, myogenic, and muscle fiber type pathways were over represented at d35 {#sec021}
--------------------------------------------------------------------------------------------

Pathway enrichment with Pathway Studio at d35 after birth identified a number of significantly enriched pathways (p\<0.05) relevant to muscle and adipose development. For example, several myogenic factors' sub-networks were significantly enriched, including networks regulated by MEF2A, MEF2C, MYH1, and TNNT2 ([S3 Table](#pone.0117607.s004){ref-type="supplementary-material"}). MEF2C was previously found to be involved in the formation of myofibers \[[@pone.0117607.ref025]\]. In addition, several sub-networks involved in fatty acid metabolism were also significantly enriched at d35, including networks regulated by ADIPOQ, CEBPA, FABP4, LDL, LEP, PGC1A, PPARG, SREBF1, and VLDL. PPARG, LEP, calmodulin, and GH1 were linked to the largest numbers of differentially expressed genes at d35. UCP2, a mitochondrial membrane transporter involved in energy balance regulation, was significantly enriched as well (p = 0.00573; [S3 Table](#pone.0117607.s004){ref-type="supplementary-material"}). Notably, WNT4 pathway members were over represented at d35 (p = 0.0227), which is consistent with previously experimentally confirmed results from this study \[[@pone.0117607.ref013]\]. The transcription factor GATA5, which is an important regulator in muscle development \[[@pone.0117607.ref026]\], was identified by Pathway Studio because its targets, including the muscle fiber type development genes *Myl2*, *Tnnc1*, *Myh7*, *Myl3*, and *Myh11*, were significantly over represented (p = 0.00133). These results indicate that genes DE due to MSTN loss of function at 13.5 d.p.c. and d35 include several important regulators of muscle and adipose development. All Pathway Studio results are presented in [S3 Table](#pone.0117607.s004){ref-type="supplementary-material"}.

Known and novel transcriptional regulatory motifs were differentially enriched in the presence or absence of functional myostatin at 13.5 d.p.c. and d35 {#sec022}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Previously, SMAD transcription factors have been implicated in MSTN signal trasnduction \[[@pone.0117607.ref027]\]; however, not all promoters of MSTN-regulated genes contain SMAD binding sites. Using DREME, several over-represented motifs were identified in DE genes at both 13.5 d.p.c. and d35 (Figs. [1](#pone.0117607.g001){ref-type="fig"} and [2](#pone.0117607.g002){ref-type="fig"}, Figures A and B in [S1 File](#pone.0117607.s001){ref-type="supplementary-material"}). Zinc-finger protein family (ZFP) binding site was the most significant motif identified at 13.5 d.p.c. Binding sites for PLAGL1, a known biomarker of disease \[[@pone.0117607.ref028]\], were over represented in genes upregulated in WT at 13.5 d.p.c. Neither *Plagl1* (q = 0.72) nor *Zfp187* (q = 0.54) was DE at 13.5 d.p.c. However, *Plagl1* itself was significantly 0.67-fold downregulated in WT at d35 (q = 0.01). In contrast, ZFP187 TF binding sites were over represented in genes downregulated in WT at 13.5 d.p.c., while the gene itself was significantly 1.21-fold upregulated in WT at d35 (q = 0.03). It is interesting that PLAGL1 binding sites were identified as over represented in genes that are more highly expressed in the WT genotype, since the similar gene *Plag1* was recently identified in a haplotype that had undergone a selective sweep in double-muscled Belgian Blue cattle \[[@pone.0117607.ref029]\].

At d35, SMAD3 binding site was found to be the most over-represented motif in DE genes upregulated in MSTN-null mice at d35, indicating its importance in MSTN signal transduction during postnatal growth. SMAD3 has proved to be necessary and sufficient for MSTN signal transduction during muscle development \[[@pone.0117607.ref030]\]. In addition, SP1 was identified as an over-represented motif in DE genes upregulated in WT at d35. *Sp1* was a DE gene and 1.29-fold upregulated in wild-type mice at d35. The SP1 transcription factor was reported to play an important role in the transcriptional activity of genes \[[@pone.0117607.ref031]\] and induction of lipogenesis via FOXO1 \[[@pone.0117607.ref032]\]. Further, SP1 is known to be important in skeletal muscle proliferation through transcriptional regulation of fibroblast growth factor receptor 1 (FGFR1) \[[@pone.0117607.ref033],[@pone.0117607.ref034]\], and differentiation by regulation of ERK5/Sp1/Klf \[[@pone.0117607.ref035]\].

An important unanswered question addressed in this study is how MSTN signals to all of the genes that it regulates. Besides SMAD3 and SP1, additional over-represented motifs were identified in DE genes between MSTN-null and wild-type mice. These results are important because they suggest novel transcriptional regulators that MSTN may signal through to directly or indirectly alter transcriptional regulation of genes within its signal transduction pathway. However, these sequence motifs have no known transcription factors that bind to them. It is possible that currently unknown sequence motifs could regulate MSTN-reactive genes at these sites. These results provide novel insights into possible mechanisms of transcriptional regulation in the context of MSTN signal transduction and indicate that there is still much to learn about MSTN signaling.

Co-expression methods identified genes known to interact with myostatin as well as novel putative pathway components {#sec023}
--------------------------------------------------------------------------------------------------------------------

Application of the RIF and PIF algorithms \[[@pone.0117607.ref011]\] to all genes in this dataset (over 34,000 annotated genes) allowed genes to be ranked as regulators, not just transcription factors. This allowed novel regulatory genes to be identified in this study. All PIF scores are provided in [S8 Table](#pone.0117607.s009){ref-type="supplementary-material"}. Genes with the 20 highest PIF scores at 13.5 d.p.c. ([Table 8](#pone.0117607.t008){ref-type="table"}) were shown by DAVID analysis to be enriched for several RNA and protein modification terms, including protein acetylation, methylation, and RNA-binding (Benjamini p\<0.05; [S9 Table](#pone.0117607.s010){ref-type="supplementary-material"}). Several cell cycle and cancer-related genes were also over represented. The highest PIF value genes from d35 ([Table 9](#pone.0117607.t009){ref-type="table"}) appear to be related to fiber type changes between MSTN-null and wild-type mice (e.g., *Tpm1*, *Ckm*, *Mylpf*, *Actn3*, *Myh4*, *Tnnt3*, *Actc1*, *Myh1*, and *Tnni2*). A DAVID enrichment analysis of the top 20 PIF genes confirms that these genes are involved in a multitude of muscle-specific structural and metabolic functions consistent with fiber type changes that occur due to MSTN inactivation ([S9 Table](#pone.0117607.s010){ref-type="supplementary-material"}).

10.1371/journal.pone.0117607.t008

###### Top 20 PIF at 13.5 d.p.c.

[\*](#t008fn001){ref-type="table-fn"}

![](pone.0117607.t008){#pone.0117607.t008g}

  ProbesetID      PIF Score   13.5 dpc q-value   Gene Symbol                                                                                                    Gene Description
  --------------- ----------- ------------------ -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1438009_at      90.96       0.0877             Hist1h2ab, Hist1h2ac, Hist1h2ad, Hist1h2ae, Hist1h2ag, Hist1h2ah, Hist1h2ai, Hist1h2an, Hist1h2ao, Hist1h2ap   histone cluster 1, H2ab, histone cluster 1, H2ac, histone cluster 1, H2ad, histone cluster 1, H2ae, histone cluster 1, H2ag, histone cluster 1, H2ah, histone cluster 1, H2ai, histone cluster 1, H2an, histone cluster 1, H2ao, histone cluster 1, H2ap
  1455725_a\_at   81.92       0.0527             Gm12657, Gm6749, Gm8029, H3f3a, H3f3b, H3f3c                                                                   predicted gene 12657, predicted pseudogene 6749, predicted gene 8029, H3 histone, family 3A, H3 histone, family 3B, H3 histone, family 3C
  1420880_a\_at   81.02       0.0911             Ywhab                                                                                                          tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide
  1450849_at      76.60       0.0206             Hnrnpu                                                                                                         heterogeneous nuclear ribonucleoprotein U
  1416365_at      75.60       0.0524             Hsp90ab1                                                                                                       heat shock protein 90 alpha (cytosolic), class B member 1
  1451285_at      74.64       0.0783             Fus                                                                                                            fusion, derived from t(12;16) malignant liposarcoma (human)
  1422848_a\_at   72.85       0.0783             Pabpn1                                                                                                         poly(A) binding protein, nuclear 1
  1437497_a\_at   72.82       0.0295             Hsp90aa1                                                                                                       heat shock protein 90, alpha (cytosolic), class A member 1
  1450740_a\_at   70.22       0.0308             Mapre1                                                                                                         microtubule-associated protein, RP/EB family, member 1
  1423667_at      69.78       0.0788             Mat2a                                                                                                          methionine adenosyltransferase II, alpha
  1460339_at      69.52       0.0961             Psma4                                                                                                          proteasome (prosome, macropain) subunit, alpha type 4
  1426407_at      68.61       0.0911             Celf1                                                                                                          CUGBP, Elav-like family member 1
  1438390_s\_at   67.97       0.0444             Pttg1                                                                                                          pituitary tumor-transforming gene 1
  1438403_s\_at   66.91       0.0487             Malat1                                                                                                         metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)
  1420613_at      66.86       0.0519             Ptp4a2                                                                                                         protein tyrosine phosphatase 4a2
  1448425_at      66.77       0.0420             Eif3a                                                                                                          eukaryotic translation initiation factor 3, subunit A
  1436884_x\_at   66.66       0.0980             Ewsr1                                                                                                          Ewing sarcoma breakpoint region 1
  1455283_x\_at   65.51       0.0719             Ndufs8                                                                                                         NADH dehydrogenase (ubiquinone) Fe-S protein 8
  1453229_s\_at   65.50       0.0914             Uqcrh                                                                                                          ubiquinol-cytochrome c reductase hinge protein
  1455546_s\_at   65.10       0.0652             Sf3a2                                                                                                          splicing factor 3a, subunit 2

\* The top 20 PIF scores with a q-value \< 0.10 are presented. For multiple probesetIDs with the same annotation, the probesetID with smallest q-value was saved.

10.1371/journal.pone.0117607.t009

###### Top 20 PIF at d35[\*](#t009fn001){ref-type="table-fn"}.
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  ProbesetID      PIF Score   d35 q-value   Gene Symbol           Gene Description
  --------------- ----------- ------------- --------------------- ----------------------------------------------------------------------------------------
  1423049_a\_at   105.15      0.0584        Tpm1                  tropomyosin 1, alpha
  1417614_at      104.42      0.0645        Ckm                   creatine kinase, muscle
  1417653_at      101.76      0.0538        Pvalb                 parvalbumin
  1448371_at      101.03      0.0230        Mylpf                 myosin light chain, phosphorylatable, fast skeletal muscle
  1418677_at      100.56      0.0022        Actn3                 actinin alpha 3
  1427026_at      98.24       0.0298        Myh4                  myosin, heavy polypeptide 4, skeletal muscle
  1417951_at      96.84       0.0594        Eno3                  enolase 3, beta muscle
  1455736_at      96.20       0.0047        Mybpc2                myosin binding protein C, fast-type
  1456588_x\_at   96.03       0.0271        Cox5b LOC100046079    cytochrome c oxidase, subunit Vb, cytochrome c oxidase, subunit 5B, mitochondrial-like
  1450118_a\_at   94.88       0.0517        Tnnt3                 troponin T3, skeletal, fast
  1418373_at      94.26       0.0283        Pgam2                 phosphoglycerate mutase 2
  1415927_at      93.14       0.0122        Actc1                 actin, alpha, cardiac muscle 1
  1416624_a\_at   92.19       0.0524        2810422J05Rik Uba52   RIKEN cDNA 2810422J05 gene, ubiquitin A-52 residue ribosomal protein fusion product 1
  1417373_a\_at   91.83       0.0255        Tuba4a                tubulin, alpha 4A
  1419737_a\_at   91.42       0.0102        Ldha                  lactate dehydrogenase A
  1418062_at      91.42       0.0121        Eef1a2                eukaryotic translation elongation factor 1 alpha 2
  1460561_x\_at   90.62       0.0041        Sepw1                 selenoprotein W, muscle 1
  1427868_x\_at   90.48       0.0089        Myh1                  myosin, heavy polypeptide 1, skeletal muscle, adult
  1426143_at      90.05       0.0358        Trdn                  triadin
  1438609_x\_at   90.02       0.0819        Tnni2                 troponin I, skeletal, fast 2

\*The top 20 PIF scores with a q-value \< 0.10 are presented. For multiple probesetIDs with the same annotation, the probesetID with smallest q-value was saved.

Several known regulators of skeletal muscle growth were identified using the RIF method. Potentially novel regulators that fit closely with known MSTN functions were also identified. The following passages present several novel possibilities regarding regulation of MSTN signal transduction.

At 13.5 d.p.c., voltage-dependent anion channel 1 (*Vdac1*) and thymosin B4 (*Tmsb4x*) were identified among the top ten RIF2 scores. The *Vdac1* gene encodes a mitochondrial porin that appears to regulate mitochondrial function by regulating the metabolites and ions that can enter the mitochondria \[[@pone.0117607.ref036],[@pone.0117607.ref037]\]. A recent study reports that treatment of HeLa cells with MSTN leads to increases in VDAC1-mediated apoptosis via BAX \[[@pone.0117607.ref038]\]. Interestingly, *Vdac1* knockout mice also have impaired exercise capacity and reduced glucose tolerance \[[@pone.0117607.ref036]\]. The *Tmsb4x* gene has been proposed to be involved in wound healing and muscle regeneration. Studies in C2C12 and satellite cell--derived primary myocytes and myoblasts indicate that *Tmsb4x* is more highly expressed at muscle wound sites and that it acts as a myoblast chemoattractant during muscle regeneration \[[@pone.0117607.ref039]\]. In the mdx mouse model of muscular dystrophy, chronic administration of TMSB4X was also found to increase the number of regenerating skeletal muscle fibers \[[@pone.0117607.ref040]\].

The *Sox2* gene was identified as a top-ten ranked RIF1 gene at 13.5 d.p.c. Several studies have documented the role of SOX2 in SMAD-mediated TGFβ signal transduction during embryonic development \[[@pone.0117607.ref041]\]. In addition, *Sox2* sustained expression is promoted by TGFβ signal transduction to promote embryonic stem cell self renewal \[[@pone.0117607.ref042]\]. Therefore, it is plausible that altered MSTN signal transduction, which acts through TGFβ, may impact SOX2 signal transduction and processes associated with stem cell renewal. Since whole embryos were used for 13.5 d.p.c., it is not possible to determine which tissues are actually affected.

At d35, *Apobec2* and *Mmp13* were identified as potential regulators based on high RIF2 and RIF1 scores, respectively. The APOBEC2 protein is an RNA-editing enzyme that is expressed almost exclusively in striated muscle and appears to be important in fiber type determination. Mouse knockouts of *Apobec2* tend to have a greater ratio of slow to fast twitch muscle, 15-20% reduction in body mass, and evidence of mild myopathy in aged mice \[[@pone.0117607.ref043]\]. Vonica et al. have defined the specific roles of APOBEC2 in right/left axis patterning in development, terminal differentiation of muscle, and inhibition of TGFβ signal transduction \[[@pone.0117607.ref044]\]. Based on studies in zebrafish, it has been suggested that APOBEC2 may mediate its effects in part by altering methylation patterns \[[@pone.0117607.ref044],[@pone.0117607.ref045]\]. The role of MMP13 in skeletal muscle has been suggested to center around myoblast migration and differentiation during muscle regeneration. Pharmacological blockade of MMP13 in C2C12 cells leads to reduced myoblast migration and differentiation, whereas overexpression leads to improved myoblast migration. Expression of *Mmp13* appears to be increased during muscle repair as well as following myoblast fusion during myotube formation. Although its exact role is unknown, it has been suggested to alter extracellular matrix remodeling during muscle regeneration \[[@pone.0117607.ref046]\].

The identification of *Atp2a2* (a.k.a. *Serca2a*) as the top-ranked RIF2 gene at d35 is particularly noteworthy, because it was previously identified as a potential modifier of MSTN in a large F2 mouse study \[[@pone.0117607.ref047]\]. The ATP2A2 calcium pump affects sarcoplasmic reticulum function and muscle fiber type. Transgenic *Atp2a2* mice exhibit cardiac hypertrophy \[[@pone.0117607.ref047]--[@pone.0117607.ref050]\]. Furthermore, pharmacological inhibition of SMAD2 in cardiomyocytes indicates that TGFβ/SMAD2 signaling regulates ATP2A2 function \[[@pone.0117607.ref051]\]. Therefore, it is very plausible that MSTN may regulate ATP2A2 in skeletal muscle to mediate changes in muscle fiber type and size.

Differentially hubbed genes that may act as regulators or key mediators in muscle and adipose development in the context of MSTN are listed in [S1 Table](#pone.0117607.s002){ref-type="supplementary-material"}. *Ctnna1* was identified as differentially hubbed at 13.5 d.p.c. despite not being DE, which indicates that MSTN may affect some regulators both directly and indirectly so as to cause or influence the differential expression of target genes. Similarly, *Bmp8b* was identified to have over 2,000 genes differentially hubbed in wild-type versus MSTN-null mice ([Fig. 4](#pone.0117607.g004){ref-type="fig"}). A recent report demonstrated that BMP8B directly regulates thermogenesis in brown adipose tissues \[[@pone.0117607.ref052]\], which indicates that MSTN may alter adipose metabolism through BMP8B. In addition, recent research identified a mutation in *Myl3* that can cause hypertrophic cardiomyopathy in infants \[[@pone.0117607.ref053]\]. In our study, over 4,000 genes were differentially hubbed with *Myl3* in wild-type compared to MSTN-null mice. Interestingly, significant enrichment of biological pathways involved in muscle development and disease occurred only in wild-type mice ([Table 7](#pone.0117607.t007){ref-type="table"}, adj.P, Benjamini \< 0.1), which is consistent with previous findings that MSTN plays an important role in phenotypes such as muscle hypertrophy or disease caused by muscle dysfunction \[[@pone.0117607.ref054],[@pone.0117607.ref055]\].

Conclusions {#sec024}
===========

Differentially expressed genes were identified between wild-type and MSTN-null mice during primary myogenesis and postnatal muscle growth, but not during secondary myogenesis. In addition, co-expression analyses identified several known and novel regulators or pathway effectors of myostatin. Regulators with known roles in muscle growth, TGFβ signaling, and mitochondrial function were identified by the RIF method. Another important finding was that genes not DE or a priori considered regulators were identified as important in differentiating wild-type and MSTN-null mice. These potential regulators would not have been identified if analyses had been limited to considering only transcription factors as regulators. Furthermore, motif enrichment analyses identified several transcription factor binding sites in genes differentially expressed due to Mstn genotype. This study demonstrates that all genes must be considered as potential regulators when trying to identify critical control points of pathway circuitry.
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